Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents

Aaron G. Bart, Goreti Morais, Venu R. Vangala, Paul M. Loadman, Klaus Pors and Emily E. Scott
Drug Metabolism and Disposition January 2022, 50 (1) 49-57; DOI: https://doi.org/10.1124/dmd.121.000642
Aaron G. Bart
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goreti Morais
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venu R. Vangala
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. Loadman
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Pors
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily E. Scott
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 50 no. 1 49-57
DOI 
https://doi.org/10.1124/dmd.121.000642
PubMed 
34607808

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received August 17, 2021
  • Accepted October 1, 2021
  • Published online December 28, 2021.

Article Versions

  • Earlier version (October 4, 2021 - 08:32).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Aaron G. Bart1,
  2. Goreti Morais,
  3. Venu R. Vangala,
  4. Paul M. Loadman,
  5. Klaus Pors, and
  6. Emily E. Scott
  1. Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  1. Address correspondence to:
    Emily E. Scott, Department of Medicinal Chemistry, University of Michigan, 428 Church St., Ann Arbor, MI 48109. E-mail: scottee{at}umich.edu; or Klaus Pors, University of Michigan, 428 Church St., Ann Arbor, MI 48109. E-mail: K.Pors1{at}bradford.ac.uk
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: October 2021 to March 2023

AbstractFullPdf
Oct 202145547371
Nov 2021237052
Dec 2021221644
Jan 20224123749
Feb 20221592039
Mar 20221551422
Apr 20221781114
May 20221371024
Jun 202284717
Jul 2022105312
Aug 2022621225
Sep 2022115820
Oct 202271822
Nov 202268920
Dec 2022681515
Jan 2023114731
Feb 2023104135
Mar 202391814

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (1)
Drug Metabolism and Disposition
Vol. 50, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

P450 Activation of Duocarmycin Prodrugs

Aaron G. Bart, Goreti Morais, Venu R. Vangala, Paul M. Loadman, Klaus Pors and Emily E. Scott
Drug Metabolism and Disposition January 1, 2022, 50 (1) 49-57; DOI: https://doi.org/10.1124/dmd.121.000642

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

P450 Activation of Duocarmycin Prodrugs

Aaron G. Bart, Goreti Morais, Venu R. Vangala, Paul M. Loadman, Klaus Pors and Emily E. Scott
Drug Metabolism and Disposition January 1, 2022, 50 (1) 49-57; DOI: https://doi.org/10.1124/dmd.121.000642
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics